Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- One Step Closer: Novel Opioid Receptor Compound In Phase I Clinical Trials
- APhA Applauds The Senate For Inclusion Of Expanded Patient Access To Medication Therapy Management Services
- FDA Warns of Contamination in Drugs for Rare Illnesses
- FDA Panel Backs Stronger Acetaminophen Warning Labels
- Added Oxygen During Stroke Reduces Brain Tissue Damage
- E-Cigarettes Subject of FDA Warning
- New Center For Cardiac Safety And Innovation Launched By URMC
- Article In December Issue Of European Urology Focuses On Health Of Infertile Men
- Research Considers Lean Mass Better For Developing Bones
- FDA Warns of Sterilizer Malfunction
St. Jude Medical Announces Leading Sponsorship Of Landmark Clinical Trial To Study Atrial Fibrillation
Posted by: admin in Pharmacy Drugs on June 17th, 2009
St. Jude Medical, Inc. (NYSE:STJ) today announced that it is the leading sponsor of the Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial. The pivotal trial, announced by Mayo Clinic, is intended to determine the effectiveness of catheter ablation (using long, narrow tubes to non-invasively reach and destroy abnormal heart tissue) in eliminating atrial fibrillation (AF), a condition in which the upper chambers of the heart beat quickly and erratically.
“The results of the CABANA trial will be significant in shaping the future of cardiac ablation as a treatment and possible cure for AF,” said Daniel J. Starks, Chairman, President and Chief Executive Officer of St. Jude Medical. “Supporting clinical trials like CABANA is an important part of our mission of advancing the practice of medicine through medical technology to help improve patient outcomes.”
The CABANA pivotal trial will last up to six years and will study the treatment of atrial fibrillation in a total of 3,000 patients and 140 centers from around the world. It will randomize patients over three years, with half undergoing catheter ablation and half receiving rate control or rhythm control drug therapy. Douglas Packer, M.D., a cardiologist at Mayo Clinic, will be the principal investigator of the clinical trial. Prior to the launch of this trial, Dr. Packer and Mayo Clinic led a 10-center, 60-patient pilot study. The results of this pilot study will be released later this summer.
The CABANA Trial will be conducted in collaboration with the Heart Rhythm Service and Biomedical Imaging Resources at Mayo Clinic, Rochester, Minn., Duke Clinical Research Institute, Durham, N.C., and CABANA Investigators. Mayo Clinic and Drs. Packer and Richard Robb, Ph.D., Mayo Clinic, have a financial interest in a mapping technology, licensed to St. Jude Medical, that may or may not be used in this research.
Source
St. Jude Medical
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.